Target
IL2R
5 abstracts
Abstract
A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors.Org: PASO Medical,
Abstract
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.Org: Departments of Cutaneous Oncology and Immunology,
Abstract
A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.Org: University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, Avenge Bio,
Abstract
Determinants of racial disparities in immune-related adverse events (irAE) with checkpoint inhibition (ICI) in melanoma.Org: New York University School of Medicine, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, University of Texas MD Anderson Cancer Center, NYU Grossman School of Medicine, Department of Population Health,
Abstract
Correlation of cancer testis antigen and interleukin expression with survival in small bowel neuroendocrine tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center,